294 related articles for article (PubMed ID: 33177436)
1. Adapting a Low-threshold Buprenorphine Program for Vulnerable Populations During the COVID-19 Pandemic.
Nordeck CD; Buresh M; Krawczyk N; Fingerhood M; Agus D
J Addict Med; 2021 Sep-Oct 01; 15(5):364-369. PubMed ID: 33177436
[TBL] [Abstract][Full Text] [Related]
2. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D
J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187
[TBL] [Abstract][Full Text] [Related]
3. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.
Harris R; Rosecrans A; Zoltick M; Willman C; Saxton R; Cotterell M; Bell J; Blackwell I; Page KR
Drug Alcohol Depend; 2022 Jan; 230():109187. PubMed ID: 34890927
[TBL] [Abstract][Full Text] [Related]
4. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
Flavin L; Tofighi B; Krawczyk N; Schatz D; McNeely J; Butner J
J Addict Med; 2022 Jan-Feb 01; 16(1):e59-e61. PubMed ID: 35120069
[TBL] [Abstract][Full Text] [Related]
5. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
[TBL] [Abstract][Full Text] [Related]
6. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
Frost MC; Zhang L; Kim HM; Lin LA
JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
[TBL] [Abstract][Full Text] [Related]
7. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic.
Tofighi B; McNeely J; Walzer D; Fansiwala K; Demner A; Chaudhury CS; Subudhi I; Schatz D; Reed T; Krawczyk N
J Addict Med; 2022 Jan-Feb 01; 16(1):e40-e43. PubMed ID: 33560696
[TBL] [Abstract][Full Text] [Related]
8. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
Currie JM; Schnell MK; Schwandt H; Zhang J
JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
[TBL] [Abstract][Full Text] [Related]
9. Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study.
Selitsky L; Nordeck C; Truong A; Agus D; Buresh ME
J Subst Use Addict Treat; 2023 Apr; 147():208981. PubMed ID: 36804350
[TBL] [Abstract][Full Text] [Related]
10. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM
Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513
[TBL] [Abstract][Full Text] [Related]
11. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.
Tilhou AS; Dague L; Saloner B; Beemon D; Burns M
JAMA Health Forum; 2022 Mar; 3(3):e220093. PubMed ID: 35977284
[TBL] [Abstract][Full Text] [Related]
12. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
13. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
[TBL] [Abstract][Full Text] [Related]
14. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
Yeo EJ; Kralles H; Sternberg D; McCullough D; Nadanasabesan A; Mayo R; Akselrod H; Catalanotti J
Harm Reduct J; 2021 Dec; 18(1):127. PubMed ID: 34886850
[TBL] [Abstract][Full Text] [Related]
15. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
[TBL] [Abstract][Full Text] [Related]
16. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
17. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
[TBL] [Abstract][Full Text] [Related]
19. Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects.
Buchheit BM; Wheelock H; Lee A; Brandt K; Gregg J
J Subst Abuse Treat; 2021 Dec; 131():108444. PubMed ID: 34098299
[TBL] [Abstract][Full Text] [Related]
20. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
